Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended			1 Months Ended	3 Months Ended						3 Months Ended		3 Months Ended		3 Months Ended		3 Months Ended			3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Feb. 28, 2013 Incline Therapeutics, Inc. [Member]	Feb. 28, 2013 Bristol-Myers Squibb [Member]	Mar. 31, 2013 Bristol-Myers Squibb [Member]	Mar. 31, 2013 In Process Research and Development [Member]	Dec. 31, 2012 In Process Research and Development [Member]	Mar. 31, 2013 Recothrom Option [Member]	Dec. 31, 2012 Recothrom Option [Member]	Jan. 31, 2013 In Process Research and Development [Member] Incline Therapeutics, Inc. [Member]	Mar. 31, 2013 Customer relationships [Member]	Dec. 31, 2012 Customer relationships [Member]	Mar. 31, 2013 Distribution agreement [Member]	Dec. 31, 2012 Distribution agreement [Member]	Mar. 31, 2013 Trademarks [Member]	Dec. 31, 2012 Trademarks [Member]	Mar. 31, 2013 Product License [Member]	Dec. 31, 2012 Product License [Member]	Feb. 28, 2013 Product License [Member] Bristol-Myers Squibb [Member]	Mar. 31, 2013 Cleviprex milstones [Member]	Dec. 31, 2012 Cleviprex milstones [Member]
Intangible Assets and Goodwill [Line Items]
Weighted Average Useful Life	6 years 1 month 6 days				2 years						8 years		5 years 8 months 12 days		8 years		5 years 8 months 12 days			13 years
Gross Carrying Amount	$ 93,406	$ 60,606									$ 7,457	$ 7,457	$ 9,125	$ 9,125	$ 3,024	$ 3,024	$ 71,800	$ 39,000		$ 2,000	$ 2,000
Accumulated Amortization	(15,475)	(10,530)									(4,487)	(4,106)	(4,069)	(3,469)	(1,820)	(1,665)	(4,930)	(1,129)		(169)	(161)
Net Carrying Amount	77,931	50,076									2,970	3,351	5,056	5,656	1,204	1,359	66,870	37,871		1,831	1,839
Collaboration term				2 years
Intangible asset										254,000									32,800
Option			57,070	57,100
Indefinite-lived Intangible Assets	$ 380,600	$ 69,500				$ 323,500	$ 69,500	$ 57,100	$ 0